Boticarium IV

  1. Medrano Albéniz, Juan
Revista:
Revista de la Asociación Española de Neuropsiquiatría

ISSN: 0211-5735

Año de publicación: 2013

Volumen: 33

Número: 118

Páginas: 409-422

Tipo: Artículo

DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Revista de la Asociación Española de Neuropsiquiatría

Referencias bibliográficas

  • (1) Agencia Española de Medicamentos y Productos Ssanitarios. Adasuve (LOXAPINA). En: Informe mensual sobre Medicamentos de Uso Humano y Productos Sanitarios, diciembre 2012 [Accesible en: http://www.aemps.gob.es/informa/informeMensual/2012/diciembre/docs/informe-mensual_diciembre-2012.pdf]
  • (2) Citrome L. Inhaled loxapine for agitation. Current Psychiatry 2013; 12(2): 31-6 [Accesible en: http://www.currentpsychiatry.com/article_pages.asp?aid=11056].
  • (3) Luz verde en la UE a la comercialización de loxapina. Jano.es, 26 de febrero de 2013 [Accesible en: http://www.jano. es/jano/actualidad/ultimas/noticias/janoes/ luz/verde/ue/comercializacion/loxapina/_f11 + i d i t e m 1 9 1 8 5 + i d t a b l a 1 ? u t m _ source=JANO&utm_medium=email&utm_ c a m p a i g n = J a n o + d i a r i o + +26%2F02%2F2013]
  • (4) Bainbridge E, Gallagher A, McDonald G, McDonald C, Ahmed M. General practitioners’ attitudes on who should manage metabolic dysregulations associated with antipsychotics. The Psychiatrist Online 2011, 35:213-215 [Accesible en: http://pb.rcpsych. org/content/35/6/213.full.pdf+html].
  • (5) Jin H, Shih PA, Golshan S, Mu- daliar S, Henry R, Glorioso DK, et al. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. J Clin Psychiatry 2013; 74: 10-8 [Abstract en: http://article.psychiatrist. com/dao_1-login.asp?ID=10008114&RS ID=29840607446454]
  • (6) Moran M. Risk-Benefit Ratio Not Favorable for Use of Atypicals in Older Adults. Psychiatric News 2012; 47 (24): 19-19 [Accesible en: http://psychnews.psychiatryonline.org/newsarticle.aspx?articleid=1487344]
  • (7) Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, et al. Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med 2012; 367: 1497-507 [Abstract en: http://www.nejm.org/doi/full/10.1056/NEJMoa1114058]
  • (8) Arehart-Treichel J. Stopping Antipsychotics Raises Relapse Risk in AD. Psychiatric News 2012; Volume 47 (23): 25-25 [Accesible en: http://psychnews.psychiatryonline.org/newsArticle. aspx?articleid=1484674].
  • (9) Comunicación Dirigida a Pro- fesionales Sanitarios sobre el riesgo de hepatotoxicidad con agomelatina ( Valdoxan/ Thymanax) [Accesible en: https://sinaem.agemed.es/CartasFarmacovigilanciaDoc/2012/ agomelatina_09-10-12.pdf]
  • (10) Kosinski EC, Rothschild AJ. Monoamine oxidase inhibitors: Forgotten treatment for depression. Current Psychiatry 2012; 11(12): 21-26 [Accesible en: http:// www.currentpsychiatry.com/article_pages. asp?AID=10931&UID=11311].
  • (11) Centro de Información online de Medicamentos de la AEMPS – CIMA. Información sobre Parnate [Accesible en: http:// www.aemps.gob.es/cima/especialidad.do?me todo=verPresentaciones&codigo=44463]
  • (12) Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013; 346:f288. doi: 10.1136/bmj.f288 [Accesible en: http://www.bmj.com/content/346/bmj.f288.pdf%2Bhtml]
  • (13) Washington NB, Brahm NC, Kissack J. Which psychotropics carry the greatest risk of QTc prolongation? Current Psychiatry 2012; 11(10): 36-39 [Accesible en: http://www.currentpsychiatry.com/article_pages.asp?AID=10780&UID=11311]
  • (14) Scarff JR. Options for treating antidepressant-induced sweating. Current Psychiatry 2013; 12(1): 51 [Accesible en: http://www.currentpsychiatry.com/article_pages.asp?AID=11007].
  • (15) Sansone RA, Sansone LA. SSRIs: bad to the bone? Innov Clin Neurosci 2012; 9: 42-7 [Accesible en: http://www.ncbi. nlm.nih.gov/pmc/articles/PMC3442753/pdf/ icns_9_7-8_42.pdf].
  • (16) Nulman I, Koren G, Rovet J, Barrera M, Pulver A, Streiner D, Feldman B. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry 2012; 169: 1165-74 [Abstract en: http://www.ncbi.nlm. nih.gov/pubmed/23128923]
  • (17) Sinclair L. Caution Urged Before Stopping Antidepressants in Pregnancy. Psuchiatric News 2012; 47 (12): 24-29 [Accesible en: http://psychnews.psychiatryonline.org/ newsArticle.aspx?articleid=1484655]
  • (18) Stephansson O, Kieler H, Haglund B, Artama M, Engeland A, Furu K, et al. Selective Serotonin Reuptake Inhibitors During Pregnancy and Risk of Stillbirth and Infant Mortality. JAMA 2013; 309: 48-54 [Abstract: http://jama.jamanetwork.com/article.aspx?articleid=1555130#Abstract].
  • (19) imenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Lander AR, Afzal S, et al. SSRI Use During Pregnancy and Risk of Stillbirth and Neonatal Mortality. Am J Psychiatry 2013; 170: 299-304 [Abstract en: http://www.ncbi.nlm.nih.gov/pubmed/23361562]
  • (20) Friedman SH, Hall, RCW. Antidepressant use during pregnancy: How to avoid clinical and legal pitfalls. Current Psychiatry 2013; 12(2): 21-25 [Accesible en: http://www.currentpsychiatry.com/article_pages.asp?aid=11049]
  • (21) Food and Drug Administration. Strattera (atomoxetine hydrochloride) capsule [Accesible en: http://www.fda.gov/Safety/ MedWatch/SafetyInformation/ucm223889. htm]
  • (22) Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ 2012; 345:e4627. doi: 10.1136/bmj.e4627 [Accesible en: http://www.bmj.com/highwire/filestream/594676/field_highwire_article_pdf/0. pdf ].
  • (23) Poulton AS, Melzer E, Tait PR, Garnett SP, Cowell CT, Baur LA et al. Growth and pubertal development of adolescent boys on stimulant medication for attention deficit hyperactivity disorder. Med J Aust 2013; 198: 29-32 [Accesible en: https://www.mja.com. au/journal/2013/198/1/growth-and-pubertaldevelopment-adolescent-boys-stimulant-medication-attention].
  • (24) Food and Drug Administration. Lamictal (lamotrigine) Tablets, Chewable Dispersible Tablets, Lamictal Orally Disinte- grating Tablets, and Lamictal XR ExtendedRelease Tablets [Accesible en: http://www. fda.gov/Safety/MedWatch/SafetyInformation/ucm268325.htm]
  • (25) Food and Drug Administration. Topamax (topiramate) tablets and sprinkle capsules. [Accesible en: http://www.fda. gov/Safety/MedWatch/SafetyInformation/ ucm195797.htm]
  • (26) Wiseman CN, y Gören JL. Can topiramate reduce nightmares in posttraumatic stress disorder. Current Psychiatry 2013; 12 (3): E1-E2. [Accesible en: http:// www.currentpsychiatry.com/article_pages. asp?aid=11139]
  • (27) Kung S, Espinel Z, Lapid MI. Treatment of nightmares with prazosin: a systematic review. Mayo Clin Proc 2012; 87: 890-900 [Accesible en: http://www. mayoclinicproceedings.org/article/S0025- 6196(12)00667-2/fulltext]
  • (28) Medicines and Healthcare products Regulatory Agency. Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions associated with the HLA-A* 3101 allele. Drug Safety Uptadet 2012; 6(5): A1 [Accesible en: http://www. mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON214944]
  • (29) Sirven JI, Noe K, Hoerth M, Drazkowski J. Antiepileptic Drugs 2012: Recent Advances and Trends. Mayo Clin Proc 2012; 87: 879-89 [Accesible en: http://www. mayoclinicproceedings.org/article/S0025- 6196(12)00678-7/fulltext]
  • (30) Europa Press. Uno de cada tres españoles ha tomado un ansiolítico en el último año, 8 de febrero de 2013 [Accesible en: http:// www.europapress.es/salud/noticia-cada-tresespanoles-utilizado-algun-medicamento-ansiedad-ultimo-ano-20130208121455.html]
  • (31) Agencia Española del Medicamento y Productos Sanitarios. Inicio de la revisión de la seguridad de los medicamentos que contienen tetrazepam, 17 de enero de 2013 [Accesible en: http://www.aemps.gob. es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2013/NI-MUH_ FV_04-2013-tetrazepam.htm].
  • (32) Billioti de Gage S, Bégaud B, Bazin F, Verdoux H, Dartigues JF, Pérès K, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ 2012; 345: e6231. doi: 10.1136/bmj.e6231 [Accesible en: http://www.bmj.com/content/345/bmj.e6231.pdf+html].
  • (33) Kripke DF, Langer RD, Kline LE. Hypnotics’ association with mortality or cancer: a matched cohort study. BMJ Open 2012; 2(1):e000850. doi: 10.1136/ bmjopen-2012-000850. Print 2012 [Accesible en: http://bmjopen.bmj.com/content/2/1/ e000850.full.pdf+html]
  • (34) Kao CH, Sun LM, Liang JA, Chang SN, Sung FC, Muo CH. Relationship of zolpidem and cancer risk: a Taiwanese population-based cohort study. Mayo Clin Proc 2012; 87: 430-6 [Accesible en: http:// download.journals.elsevierhealth.com/pdfs/ journals/0025-6196/PIIS0025619612003059. pdf].
  • (35) Phillips BA. Insomnia, hypnotic drug use, and patient well-being: first, do no harm. Mayo Clin Proc 2012; 87: 417-8 [Accesible en: http://download.journals.elsevierhealth.com/pdfs/journals/0025-6196/ PIIS0025619612003060.pdf].
  • (36) Huang HY, Hsu YT, Wu YC, Chiou SM, Kao CH, Tsai MC, et al. Zolpidem improves neuropsychiatric symptoms and motor dysfunction in a patient with Parkinson’s disease after deep brain stimulation. Acta Neurol Taiwan 2012; 21: 84-6 [Accesible en: http://www.ant-tnsjournal.com/ Mag_Files/21-2/007.pdf]
  • (37) Food and Durg Administration. Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses, Including Ambien, Ambien CR, Edluar, and Zolpimist; January 10th, 2013 [Accesible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm334738. htm?source=govdelivery]
  • (38) Instituto Nacional de Toxicología y Ciencias Forenses. Memoria 2011 [Accesible en: https://www.administraciondejusticia.gob.es/paj/PA_WebApp_SGNTJ_ NPAJ/descarga/MEMORIA_INTCF_2011. pdf?idFile=da103022-3afc-44b4-9b3b87eb2338e490]
  • (39) Chang CM, Wu EC, Chen CY, Wu KY, Liang HY, Chau YL, et al. Psychotropic Drugs and Risk of Motor Vehicle Accidents: a Population-based Case-Control Study. Br J Clin Pharmacol 2012. doi: 10.1111/j.1365- 2125.2012.04410.x [Accesible en: http:// onlinelibrary.wiley.com/doi/10.1111/j.1365- 2125.2012.04410.x/pdf].
  • (40) Kuehn BM. FDA warning: Driving may be impaired the morning following sleeping pill use. JAMA 2013; 309: 645-6 [Accesible en: http://jama.jamanetwork.com/ article.aspx?articleid=1653519].
  • (41) Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ 2012; 345:e8343. doi: 10.1136/bmj.e8343 [Accesible en: http:// www.bmj.com/content/345/bmj.e8343]
  • (42) Kollen BJ, van der Veen WJ, Groenhof F, Donker GA, van der Meer K. Discontinuation of reimbursement of benzodiazepines in the Netherlands: does it make a difference? BMC Fam Pract 2012; 13:111. doi: 10.1186/1471-2296-13-111. [Accesible en: http://www.biomedcentral.com/1471- 2296/13/111]
  • (43) Dormuth CR, Miller TA, Huang A, Mamdani MM, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network. Effect of a centralized prescription network on inappropriate prescriptions for opioid analgesics and benzodiazepines. CMAJ. 2012; 184(16): E852-6. doi: 10.1503/ cmaj.120465 [Accesible en: http://www.cmaj. ca/content/184/16/E852.full.pdf+html].
  • (44) Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller RL, et al. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 2011; 68: 1195-206 [Accesible en: http://archpsyc.jamanetwork.com/ article.aspx?articleid=1107363]
  • (45) Food and Drug Administration. FDA Drug Safety Communication: Safety review update of Chantix (varenicline) and risk of cardiovascular adverse events, 12/12/12. [Accesible en: http://www.fda.gov/Drugs/ DrugSafety/ucm330367.htm].
  • (46) Dent R, Blackmore A, Peterson J, Habib R, Kay GP, Gervais A, Taylor V, Wells G. Changes in body weight and psychotropic drugs: a systematic synthesis of the literature. PLoS One 2012; 7(6): e36889. doi: 10.1371/journal.pone.0036889 [Accesible en: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0036889]
  • (47) Fankhauser MP, Ellingrod MS. Drug interactions with tobacco smoke: Implications for patient care. Current Psychiatry 2013; 12(1): 12-6 [Accesible en: http:// www.currentpsychiatry.com/article_pages. asp?aid=11009].
  • (48) Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry 2012; 73: 1220-3 [Abstract en: http://www.ncbi.nlm.nih.gov/pubmed/22939118]
  • (49) Medicines and Healthcare pro- ducts Regulatory Agency. Drug Safety Alert: Roflumilast (Daxas): risk of suicidal behaviour – avoid use in patients with previous or existing psychiatric symptoms and discontinue treatment if new or worsening psychiatric symptoms occur. January 2013 [Accesible en: http://www.mhra.gov.uk/Safetyinformation/ DrugSafetyUpdate/CON228753]
  • (50) Drazen JM.Transparency for clinical trials--the TEST Act. N Engl J Med 2012; 367: 863-4 [Accesible en: http://www. nejm.org/doi/pdf/10.1056/NEJMe1209433]
  • (51) Brodin T, Fick J, Jonsson M, Klaminder J. Dilute concentrations of a psychiatric drug alter behavior of fish from natural populations. Science 2013; 339: 814-5. doi: 10.1126/science.1226850 [Abstract en: http://www.ncbi.nlm.nih.gov/pubmed/23413353].
  • (52) Siegel-Itzkovich J. Viagra makes flowers stand right. BMJ 1999; 319: 274 [Accesible en: http://bmj.bmjjournals.com/cgi/ reprint/319/7205/274/a?maxtoshow=&HITS =10&hits=10&RESULTFORMAT=1&author1=Siegel-Itzkovich&searchid=1070179103 437_131&stored_search=&FIRSTINDEX=0 &sortspec=relevance&fdate=1/1/1999&tdate =12/31/1999&resourcetype=1,2,3,4,10].
  • (53) Benotti MJ, Trenholm MJ, Vanderford BJ, Holady JC, Stanford BD et al. Pharmaceuticals and Endocrine Disrupting Compounds in U.S. Drinking Water. Environ Sci Technol 2009; 43: 597–603 [Abstract en: http://www.ncbi.nlm.nih.gov/pubmed/19244989].
  • (54) Fent K, Weston AA, Caminada D. Ecotoxicology of human pharmaceuticals. Aquat Toxicol 2006; 76: 122-159 [Abstract en: http://www.ncbi.nlm.nih.gov/pubmed/16257063].
  • (55) Gaworecki KM, Klaine SJ. Behavioral and biochemical responses of hybrid striped bass during and after fluoxetine exposure. Aquat Toxicol 2008; 88: 207-213 [Abstract en: http://www.ncbi.nlm.nih.gov/ pubmed/18547660].
  • (56) De Lange HJ, Noordoven W, Murk AJ, Lürling M, Peeters ET. Behavioural responses of Gammarus pulex (Crustacea, Amphipoda) to low concentrations of pharmaceuticals Aquat Toxicol 2006; 78: 209- 216 [Abstract en: http://www.ncbi.nlm.nih. gov/pubmed/16624423].
  • (57) Fong PP. Zebra mussel spawning is induced in low concentrations of putative serotonin reuptake inhibitors. Biol Bull 1998; 194: 143-149 [Accesible en: http://www.biolbull.org/cgi/reprint/194/2/143.pdf].
  • (58) Guler Y, Ford AT. Anti-depressants make amphipods see the light Aquatic Toxicology 2010, 99: 397-404 [Abstract en: http://www.ncbi.nlm.nih.gov/ pubmed/20591511].
Fuente de los datos: Dialnet